

**FENWICK & WEST LLP**

SAN FRANCISCO OFFICE | EMBARCADERO CENTER WEST

275 BATTERY ST., SUITE 1500 | SAN FRANCISCO, CA 94111

TEL 415.875.2300 | FAX 415.281.1350 | WWW.FENWICK.COM

FACSIMILE TRANSMISSION**OFFICIAL****CONFIDENTIAL**

DATE: 7/21/04

ATTORNEY DOCKET NO: 23714-79924S

TO:

| NAME | FAX NO. | PHONE NO. |
|--------------------------------------|----------------|-----------|
| USPTO GAU 1644 Examiner Ewoldt | (703) 872-9306 | |

FROM: Susan T. Hubl, Ph.D.
Patent Agent

PHONE: (415) 875-2316

NUMBER OF PAGES WITH COVER PAGE: 7

ORIGINAL WILL NOT FOLLOW

MESSAGE:

US Patent Application No: 10/773,356
IDS**CAUTION - CONFIDENTIAL**

THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS PRIVILEGED AND CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY NAMED ABOVE OR THEIR DESIGNEE. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPY OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US AT THE ABOVE ADDRESS VIA THE U.S. POSTAL SERVICE. THANK YOU.

IF YOU DO NOT RECEIVE ALL OF THE PAGES, OR IF THEY ARE NOT CLEAR,
PLEASE CALL _____ AT _____ AS SOON AS
POSSIBLE.

+

| | | | | | | | |
|--|--|--|------------------------|-----------------------|------------------|--|--|
| 0001/PTO Rev. 10/95 | | U.S. Department of Commerce Patent and Trademark Office | | Application Number | 10/773,356 | | |
| TRANSMITTAL FORM <i>(to be used for all correspondence during pendency of filed application)</i> | | | | Filing Date | FEBRUARY 5, 2004 | | |
| | | | | First Named Inventor | WEINER | | |
| | | | | Group Art Unit Number | 1644 | | |
| | | | | Examiner Name | EWOLDT | | |
| Total Number of Pages in This Submission | | 7 | Attorney Docket Number | | 23714-7992/US | | |

| ENCLOSURES (check all that apply) | |
|---|---|
| <input type="checkbox"/> Fee Transmittal Form (in duplicate) <input type="checkbox"/> Check Enclosed <input type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Response to Notice to File Missing Parts <input type="checkbox"/> Assignment & Recordation Cover Sheet <input type="checkbox"/> Declaration <input type="checkbox"/> Power of Attorney <input type="checkbox"/> Application Data Sheet <input checked="" type="checkbox"/> Information Disclosure Statement & PTO/SB/08A (5 pp) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Request for Correction of Recorded Assignment <input type="checkbox"/> Amendment/Response: [] Page(s) <input type="checkbox"/> After Final <input type="checkbox"/> Status Request <input type="checkbox"/> Revocation and Substitute Power of Attorney | <input type="checkbox"/> Issue Fee Transmittal <input type="checkbox"/> Letter to Chief Draftsperson <input type="checkbox"/> Formal Drawing(s): [] Sheet(s) of Figure(s) [] <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group <i>(Appeal Notice, Brief, Reply Brief)</i> <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> After Allowance Communication to Group <input checked="" type="checkbox"/> FAX COVER SHEET <input type="checkbox"/> _____ <input type="checkbox"/> _____ <input type="checkbox"/> _____ <input type="checkbox"/> _____ <input type="checkbox"/> _____ |
| REMARKS: | |

| SIGNATURE OF ATTORNEY OR AGENT | | | |
|--------------------------------|--|--------|---------|
| Signature: | <i>Susan T. Hubl</i> | | |
| Attorney/Reg. No.: | SUSAN T. HUBL, PH.D., PATENT AGENT/ REG NO. 47,668 | Dated: | 7/21/04 |

| CERTIFICATE OF FACSIMILE TRANSMISSION | | | |
|--|----------------------|--------|---------|
| I hereby certify that this correspondence, including the enclosures identified above, is being transmitted on the date shown below via facsimile to: Commissioner for Patents at the facsimile number indicated below. | | | |
| Signature: | <i>Susan T. Hubl</i> | | |
| Typed or Printed Name: | SUSAN T. HUBL | Dated: | 7/21/04 |
| Facsimile Number: | 1-703-872-8306 | | |

23714/07992/SF/5125124.1
07/21/04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: WEINER ET AL
APPLICATION NO.: 10/773,356
FILING DATE: FEBRUARY 5, 2004
TITLE: T CELL VACCINATION FOR THE TREATMENT OF
MULTIPLE SCLEROSIS
EXAMINER: EWOLDT
GROUP ART UNIT: 1644
ATTY. DKT. NO.: 23714-07992US

RECEIVED

JUL 21 2004

OFFICIAL

| CERTIFICATE OF FACSIMILE TRANSMISSION | | | |
|---|----------------------|--------|---------|
| I hereby certify that this correspondence, including the enclosures identified above, is being transmitted on the date shown below via facsimile to Commissioner for Patents at the facsimile number indicated below. | | | |
| Signature: | <i>Susan T. Hubl</i> | | |
| Typed or Printed Name: | SUSAN T. HUBL | Dated: | 7/21/04 |
| Facsimile Number: | 1-703-872-9306 | | |

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
Under 37 CFR §§ 1.56 and 1.97-98

SIR:

Pursuant to the provisions of 37 CFR §§ 1.56 and 1.97-98, enclosed herewith is modified form PTO/SB/08A listing references for consideration by the Examiner.

The filing of this Information Disclosure Statement shall not be construed as a representation regarding the completeness of the list of references, or that inclusion of a reference in this list is an admission that it is prior art or is pertinent to this application, or that a search has been made, or as an admission that the information listed is, or may be considered to be, material to patentability, or that no other material information exists, and shall not be construed as an admission against interest in any manner.

This Information Disclosure Statement is being filed:

- ☒ within three months of the filing date of the application, or date of entry into the national stage of an international application, or before the mailing date of a first office action on the merits, whichever event last occurred;
- ☒ This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior application No. 09/156,509 filed on SEPTEMBER 17, 1998, and the references cited

23714/07992/SF/5125123.1
07/21/04

PATENT

therein are hereby referenced, but are not required to be provided in this application under 37 CFR § 1.98(d).

- ☒ Applicant submits that no fee is required for the consideration of this Information Disclosure Statement.

Consideration of the listed references and favorable action are solicited.

Respectfully submitted,
LESLIE WEINER ET AL

Dated: 7/21/04

By: *Susan T. Hubl*
Susan T. Hubl, Patent Agent, Reg. No.: 47,668
Fenwick & West LLP
Silicon Valley Center
801 California Street
Mountain View, CA 94041
Tel.: (415) 875-2316
Fax.: (650) 938-5200

| | | | |
|--|---|--------------------------|------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Application No. | 10/773,356 |
| | | Filing Date | February 5, 2004 |
| | | First Named Inventor | Weiner et al. |
| | | Art Unit | 1644 |
| | | Examiner Name | EWOLDT |
| Sheet | 1 | of | 3 |
| | | Attorney Docket Number | 23714-07992/US |

sent 7/21/04

| U.S. PATENT DOCUMENTS | | | | |
|-----------------------|-----------------------|--|--------------------|--|
| Examiner Initials* | Cite No. ¹ | Document No. Number - Kind Code ² (if known) | Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document |
| | A1 | US-5,849,886 | 12-15-1998 | MAATTA ET AL |

| FOREIGN PATENT DOCUMENTS | | | | |
|--------------------------|-----------------------|--|--------------------------------|--|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ² - Number ³ Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document |
| | | WO 91/015225 | 17-10-1991 | BRIGHAM AND WOMEN'S HOSPITAL ET AL |
| | | WO 90/010448 | 20-09-1990 | COHEN ET AL |
| | | WO 03/024393 A2 | 12-09-2002 | OPEXA PHARMACEUTICALS ET AL |

| OTHER REFERENCES - NON-PATENT LITERATURE DOCUMENTS | | | | |
|--|-----------------------|--|--|--|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | | |
| | | ACHA-ORBEA, H., et al., "Limited heterogeneity of T cell receptors from lymphocytes medicating autoimmune encephalomyelitis allows specific immune intervention," <i>Cell</i> , (1988) 54: 263-273 | | |
| | | BEN-NUN, A. ET AL. "The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease." <i>J. Neurol</i> (1996) 243(Suppl 1):S14-S22 | | |
| | | BEN-NUN, A., ET AL., "Restricted T-Cell receptor Vβ gene usage by myelin base protein-specific T-Cell clones in multiple sclerosis: Predominant genes vary in individuals," <i>Proc. Nat. Acad. Sci USA</i> (1991) 88: 2466-2470 | | |
| | | BOURDETTE, D.N., ET AL., "Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic Vβ5.2 and Vβ6.1 CDR2 peptides," <i>J. Immunol.</i> (1994) 152:2510-2519 | | |
| | | CHOU, Y.K., ET AL., "Immunity to TCR peptides in multiple sclerosis. II. T Cell Recognition of Vβ5.2 and Vβ6.1 CDR2 peptides," <i>J. Immunol.</i> (1994) 152:2520-2529 | | |
| | | COHEN, PL. "Systemic autoimmunity" from <i>Fundamental Immunology</i> , (1999) pages 1067 and 1083. William E. Paul, editor, Lippencott-Raven, Publishers. | | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|--|---|--------------------------|------------------|------------------------|----------------|
| Substitute for form 1448A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>Sent 7/21/04</i> | | Complete if Known | | | |
| | | Application No. | 10/773,356 | | |
| | | Filing Date | February 5, 2004 | | |
| | | First Named Inventor | Weiner et al. | | |
| | | Art Unit | 1644 | | |
| | | Examiner Name | EWOLDT | | |
| Sheet | 2 | of | 3 | Attorney Docket Number | 23714-07992/US |

| OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS | | | |
|--|-----------|--|----|
| Examiner Initials* | Cite No.† | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T‡ |
| | | CORREALE, J., ET AL. "Isolation and characterization of CD8+ T-cell clones (TCCs) that recognize autologous-activated CD4+ TCCs from chronic progressive multiple sclerosis (MS) patients: implications for immunoregulation in MS," <u>Neurology</u> , (February 1996) 46: Suppl. S, p. A280 | |
| | | CORREALE, J. ET AL. "T-cell vaccination in secondary progressive multiple sclerosis," <u>Journal of Neuroimmunology</u> , (2000) 107:130-139. | |
| | | GOLD, D.P., ET AL. "Results of a phase 1 clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCR Vβ6 CDR 2 peptide," <u>J. Neuroimmunol.</u> , (1997) 76 pp. 29-38. | |
| | | HAFLER, D.A., ET AL. "T cell vaccination in multiple sclerosis: A preliminary report," <u>Clin. Immunol Immunopath.</u> (1992) 62(3), pp. 307-313 | |
| | | HOWELL, M.D., ET AL. "Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides," <u>Science</u> , (1989) 246:668-670. | |
| | | LIBLAU, R., ET AL., "T cell response to myelin basic protein epitopes in multiple sclerosis patients and healthy subjects," <u>Eur. J. Immunol.</u> , (1991) 21:1391-1395. | |
| | | LOHSE, A.W., ET AL. "Control of experimental autoimmune encephalomyelitis by T cells responding to activated T cells," <u>Science</u> (1989) 244:820-822. | |
| | | MEDAER, R., ET AL. "Prospects for T cell vaccination in multiple sclerosis," <u>BioDrugs</u> , (1997), 8:1-5. | |
| | | MILLER, STEPHEN D., ET AL. "The immunopathogenesis and regulation of T-cell mediated demyelinating disease," <u>Immunology Today</u> , (1994) 15:356-361. | |
| | | MORELAND, L., ET AL. "Vaccination against rheumatoid arthritis," <u>BioDrugs</u> , (1997) 8:87-95. | |
| | | STINISSEN, P., ET AL. "Vaccination with autoreactive T cell clones in multiple sclerosis: Overview of immunological and clinical data," <u>Journal of Neuroscience Research</u> (1996) 45:500-511. | |
| | | VAN DER AA ET AL. "T cell vaccination in multiple sclerosis patients with autologous CSF derived activated T cells: results from a pilot study," <u>Clin. Exp. Immunol.</u> (2003) 131:155-168. | |
| | | VAN LAAR, J., ET AL. "Effects of inoculation with attenuated autologous T cells in patients with rheumatoid arthritis," <u>Journal of Autoimmunity</u> , (1993) 6:159-167 | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Applicant's unique citation designation number (optional). ‡See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. §Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ***Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|---|---|----|--------------------------|------------------------|----------------|
| Substitute for form 1449A/PTO | | | Complete if Known | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>sent 7/21/04</i> | | | Application No. | 10/773,356 | |
| | | | Filing Date | February 5, 2004 | |
| | | | First Named Inventor | Weiner et al. | |
| | | | Art Unit | 1644 | |
| | | | Examiner Name | EWOLDT | |
| Sheet | 3 | of | 3 | Attorney Docket Number | 23714-07992/US |

| OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS | | | |
|--|-----------|---|----|
| Examiner Initials* | Cite No.† | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T‡ |
| | | VANDENBARK, A.A., ET AL. "T Cell receptor peptides in treatment of autoimmune disease: rational and potential," <u>J. Neurosci. Res.</u> , (1996) 43:391-402 | |
| | | VANDENBARK, A.A., ET AL. "Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis," <u>Nature</u> (1989) 341:541-544 | |
| | | WEINER, L., ET AL., "Isolation and characterization of CD8+ and gamma-delta T cells specific for autologous autoreactive CD4+ T cell clones from multiple sclerosis patients and healthy control subjects," <u>Neurology</u> , (March 1997), 48 (3) Suppl. 2, pp. A59-A60 | |
| | | ZHANG, J., ET AL. "T-cell vaccination in autoimmune diseases – from laboratory to clinic," <u>Human Immunol.</u> (1993) 38, pp. 87-96 | |
| | | ZHANG, J., J., ET AL. "MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination," <u>Science</u> , (1993) 261:1451-1454 | |
| | | ZHANG, J., ET AL. "Myelin basic protein-reactive T cells in multiple sclerosis: pathologic relevance and therapeutic targeting," <u>Cytotechnology</u> (1994) 16:181-187 | |
| | | ZHANG ET AL. In vivo clonotypic regulation of human myelin basic protein reactive T cells by T cell vaccination," <u>Journal of Immunology</u> ((1995) 155:5868-5877 | |
| | | ZHANG, J. "Multiple Sclerosis: Perspectives on Autoimmune Pathology and Prospects for Therapy," <u>Current Neurology</u> (1995) 15:115-155 | |

23714/07992/SF/5122822.1

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809.
Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Applicant's unique citation designation number (optional). ‡See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. §Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ***Applicant is to place a check mark here if English language Translation is attached.